Dabrafenib

Sulfuric acid (H2SO4), Hydrogen peroxide (H2O2) solution (30%wt in H2O), 3-(Trimethoxysilyl) propyl methacrylate (TMSPMA), Methanol, Acetic acid, Chloroform (CHCl3), 2,2-Dimethoxy-2phenylacetophenone (DMPA), Ethylene glycol dimethacrylate (EGDMA), Poly(ethylene glycol) methacrylate (Mn = 500 gmol -1 , PEGMA), Methacrylic acid (MAA), 2-Aminoquinoline (2-AQ), Fetal bovine serum (FBS) were purchased from Sigma-Aldrich, UK. Dimethyl sulfoxide (DMSO) was purchased from Honeywell, UK. Dabrafenib was purchased from Adooq bioscience, USA. All the chemicals were of analytical grade and used without further purification. Deionised water (DI-water) was obtained from water purification system (PURELAB Option S/R, ELGA). Phosphate buffered saline (PBS) was freshly prepared by dissolving PBS tablets (Oxoid, UK) in DI-water, which comprised Sodium chloride (8.0 mg mL -1 ), Potassium chloride (0.2 mg mL -1 ), Disodium hydrogen phosphate (1.15 mg mL -1 ), Potassium dihydrogen phosphate (0.2 mg mL -1 ), pH 7.3 ±0.2, at 25°C.

Regorafenib, M-2, M-5, and elacridar were purchased from Toronto Research Chemicals (North York, ON). Ko143 was from Sigma-Aldrich (St. Louis, MO). Imatinib mesylate was from Focus Biomolecules (Plymouth Meeting, PA). Afatinib, bortezomib, cabozantinib, carfilzomib, dabrafenib, dacomitinib, dasatinib, lapatinib, lenvatinib, pazopanib, ponatinib, ruxolitinib, tofacitinib, trametinib, vandetanib, and vemurafenib were from AdooQ Bioscience (Irvine, CA). Sorafenib was from LKT Laboratories Inc. (St. Paul, MN). Sunitinib was from Synkinase Pty Ltd. (San Diego, CA). Crizotinib was from LC Laboratories Inc. (Woburn, MA). Gefitinib and erlotinib were from Cayman Chemical Company (Ann Arbor, MI). Nilotinib was from ChemScene, LLC (Monmouth Junction, NJ). All other chemicals and reagents were of analytical grade and were obtained from commercial sources.